Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Go back to Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.40 -0.56 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.96 | 52 Week High | $333.65 | |||
| Open | $200.57 | 52 Week Low | $223.02 | |||
| Day High | $203.45 | P/E | 25.53 | |||
| Day Low | $199.15 | EPS | $7.81 | |||
| Volume | 455,023 | |||||
| (NASDAQ: DNLI) | Delayed: 21.42 +0.40 (1.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.02 | 52 Week High | $ | |||
| Open | $21.02 | 52 Week Low | $ | |||
| Day High | $22.15 | P/E | N/A | |||
| Day Low | $20.92 | EPS | $ | |||
| Volume | 1,399,703 | |||||
